METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

NCT05504252 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Adenocarcinoma
Mucinous Adenocarcinoma
Signet Ring Cell Adenocarcinoma

Interventions

DRUG: Nivolumab
DRUG: Oxaliplatin

Sponsor

University Hospital, Akershus

Collaborators

[object Object]
[object Object]